Cardiovascular Revascularization Medicine最新文献

{"title":"Editorial: Improving outcomes in High Risk PE - a glimpse of the future?","authors":"Andrew Sharp , Sripal Bangalore","doi":"10.1016/j.carrev.2024.08.019","DOIUrl":"10.1016/j.carrev.2024.08.019","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 62-63"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should all patients with severe aortic stenosis have TAVR now?","authors":"Spencer B. King III","doi":"10.1016/j.carrev.2025.01.001","DOIUrl":"10.1016/j.carrev.2025.01.001","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 105-106"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143298391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microcirculatory status after intravascular lithotripsy: The MARVEL study","authors":"Frederic Bouisset , Javier Escaned , Daniel Munhoz , Takuya Mizukami , Ruiko Seki , Carlos H. Salazar , Jeroen Sonck , Nieves Gonzalo , Bernard De Bruyne , Carlos Collet","doi":"10.1016/j.carrev.2024.08.009","DOIUrl":"10.1016/j.carrev.2024.08.009","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 103-104"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravascular lithotripsy for the treatment of peri-stent calcific lesions in saphenous vein grafts: A case series report","authors":"Maura Meijer,&nbsp;Federico Oliveri,&nbsp;Martijn J.H. van Oort,&nbsp;Brian O. Bingen,&nbsp;Frank van der Kley,&nbsp;J. Wouter Jukema,&nbsp;Ibtihal Al Amri,&nbsp;J.M. Montero-Cabezas","doi":"10.1016/j.carrev.2024.07.004","DOIUrl":"10.1016/j.carrev.2024.07.004","url":null,"abstract":"<div><h3>Background</h3><div>Coronary artery bypass grafting (CABG) is a cornerstone treatment for coronary artery disease, with the use of saphenous vein grafts (SVGs) being prevalent. However, SVGs are susceptible to high failure rates due to graft inflammation, intimal hyperplasia, and atherosclerosis, leading to a substantial number of patients requiring revascularization. Percutaneous coronary intervention (PCI) of SVGs poses unique challenges, including increased risk of distal embolization and perforation due to the grafts' structure and atherosclerotic nature. The role of intravascular lithotripsy (IVL) in calcific SVG lesions has not been elucidated.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed four cases of patients treated with IVL for SVG stenosis at Leiden University Medical Centre between May 2019 and December 2023. Quantitative coronary analysis and intravascular ultrasound were utilized to assess procedural success and mid- to long-term clinical outcomes were reported as well.</div></div><div><h3>Results</h3><div>In all 4 cases, IVL was performed in stent (2 due to calcific in-stent neoatherosclerosis; 2 bail-out due to extrinsic stent calcification). No major adverse cardiovascular events (MACE) were reported during mid- to long-term follow-up. The procedure demonstrated effective calcium cracking, leading to optimal stent expansion and minimal residual stenosis with a low risk of procedural complications.</div></div><div><h3>Conclusions</h3><div>IVL represents a promising approach for managing calcified peri-stent SVG lesions, showing potential for safe and effective revascularization with minimal complications. These findings suggest that IVL could be incorporated into the treatment paradigm for calcified peri-stent SVG stenosis, warranting further investigation in larger, prospective studies to validate its efficacy and safety.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 85-91"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141761684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Does troponin I overestimate periprocedural myocardial infarction more than troponin T in PCI patients? The devil is in the details","authors":"Francesco Costa ,&nbsp;Mamas Mamas","doi":"10.1016/j.carrev.2024.07.019","DOIUrl":"10.1016/j.carrev.2024.07.019","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 20-22"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of standardization of insertion and removal of percutaneous left ventricular assist device","authors":"Jacob Lee ,&nbsp;Suma Gondi ,&nbsp;Kristina Gifft ,&nbsp;Jinli Wang ,&nbsp;Venugopal Bhattad ,&nbsp;Chirag Bavishi ,&nbsp;Poorna R. Karuparthi ,&nbsp;Arun Kumar ,&nbsp;Albert Chan ,&nbsp;Hitoshi Matsukage ,&nbsp;Taishi Hirai","doi":"10.1016/j.carrev.2024.05.035","DOIUrl":"10.1016/j.carrev.2024.05.035","url":null,"abstract":"<div><h3>Background</h3><div>The effect of standardizing an insertion and removal protocol for pVAD devices has not been previously described.</div></div><div><h3>Objectives</h3><div>We sought to evaluate clinical outcomes in patients who underwent pVAD insertion pre- and post-protocol standardization.</div></div><div><h3>Methods</h3><div><span>All patients who underwent pVAD insertion that remained in place at index procedure completion between January 2017 and September 2023 at a single academic center for both high-risk PCI and cardiogenic shock indications were included in the study. The primary outcome was the incidence of </span>limb ischemia<span> and major bleeding before and after the protocol initiation. Secondary outcomes included in-hospital and 30-day MACCE rate (death, myocardial infarction, stroke, emergent CABG), and how often the operators followed the protocol.</span></div></div><div><h3>Results</h3><div><span>A total of 89 patients had pVAD left in place (29 pre-protocol initiation and 60 post-protocol initiation). There was a significant decrease in incidence of limb ischemia post-protocol initiation compared to pre (17.2 % vs 1.7 %, </span><em>p</em> = 0.01) but no difference in bleeding incidence (13.8 % vs 20.0 %, <em>p</em><span> = 0.47). Adherence increased in all components of the protocol except for right heart catheterization.</span></div></div><div><h3>Conclusion</h3><div>Standardization of an insertion and removal protocol for pVAD devices led to a statistically significant decrease in limb ischemia in a high-risk patient population.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 64-68"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in transcatheter aortic valve replacement (TAVR) patients requiring red blood cell transfusion: A nationwide perspective","authors":"Mohsin Sheraz Mughal ,&nbsp;Hasan M. Mirza ,&nbsp;Amit Bansal ,&nbsp;Sundeep Kumar ,&nbsp;Ali Ghani ,&nbsp;Alon Yarkoni ,&nbsp;Fahad Waqar ,&nbsp;Najam Wasty ,&nbsp;Afzal Rehman","doi":"10.1016/j.carrev.2024.06.019","DOIUrl":"10.1016/j.carrev.2024.06.019","url":null,"abstract":"<div><h3>Background</h3><div><span><span>Transcatheter aortic valve replacement<span> (TAVR) can be complicated by anemia due to periprocedural </span></span>bleeding, hemolysis, vascular events, or significant bleeding associated with </span>antiplatelet therapy.</div></div><div><h3>Objective</h3><div>We used the National Inpatient Sample (NIS) database to study the outcomes of patients who underwent TAVR and developed significant anemia requiring red blood cell (RBC) transfusion.</div></div><div><h3>Methods</h3><div><span>This is a retrospective cohort study utilizing the NIS database from 2016 to 2017. We identified patients who underwent TAVR and required RBC transfusion using ICD-10 and PCS-10 codes. The primary outcome was all-cause inpatient mortality, and the secondary outcomes were the cost of hospitalization and length of stay (LOS). Student </span><em>t</em><span>-test, Chi-square, and ANOVA were utilized for statistical analysis where applicable. Multivariate logistic regression was used to adjust for potential confounders. STATA 15.0 was utilized for data analysis.</span></div></div><div><h3>Results</h3><div><span>A total of 18,325 patients underwent TAVR in 2016–2017. Among them, 6.7 % of patients required RBC transfusion. Patients were relatively older in the transfusion group (81 yrs vs 79 yrs; p &lt; 0.001). The mean cost of hospitalization was higher in the transfusion group (283,153 USD vs 208,939 USD; p &lt; 0.001). The mean length of stay (LOS) was higher in the transfusion group (9.0 days vs 4.3 days; p &lt; 0.001). Patients in the transfusion group had higher inpatient all-cause mortality compared to patients without transfusion (6.1 % vs 1.3 %; odds ratio 4.94; p &lt; 0.001, 95 % CI 3.7–6.4). Inpatient mortality and LOS didn't differ by race or sex in the transfusion group. All-cause mortality, LOS, and cost of hospitalization were independently increased by transfusion after adjusting for potential confounders i.e. sex, race, hospital teaching status, hospital region, heart block, pacemaker, arrhythmias, heart failure, diabetes, pulmonary hypertension, </span>CKD, and others using multivariate logistic regression.</div></div><div><h3>Conclusion</h3><div><span>In patients undergoing TAVR, blood transfusion was associated with </span>adverse outcomes<span> including increased mortality, length of stay, and cost of hospitalization. The role of careful patient selection, judicious use of antiplatelets, anticoagulants, and pre-procedural optimization of anemia needs further investigation to optimize patient outcomes.</span></div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 50-53"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: C-reactive protein and TAVR: Impact of inflammation on patient outcomes","authors":"Placido Maria Mazzone,&nbsp;Davide Capodanno","doi":"10.1016/j.carrev.2024.08.012","DOIUrl":"10.1016/j.carrev.2024.08.012","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 76-77"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Response to “Outcomes in transcatheter aortic valve replacement (TAVR) patients requiring red blood cell transfusion: A nationwide perspective”","authors":"David Gittess ,&nbsp;R. David Anderson","doi":"10.1016/j.carrev.2024.08.014","DOIUrl":"10.1016/j.carrev.2024.08.014","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 54-55"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete versus culprit-only percutaneous coronary intervention in elderly patients with acute coronary syndrome and multivessel coronary artery disease: A systematic review and meta-analysis","authors":"Ancy Jenil Franco ,&nbsp;Mrinal Murali Krishna ,&nbsp;Meghna Joseph ,&nbsp;Chidubem Ezenna ,&nbsp;Zeynep Eylul Bakir ,&nbsp;Renan Yuji Ura Sudo ,&nbsp;Catherine Wegner Wippel ,&nbsp;Mahmoud Ismayl ,&nbsp;Andrew M. Goldsweig ,&nbsp;Ilayaraja Uthirapathy","doi":"10.1016/j.carrev.2024.05.040","DOIUrl":"10.1016/j.carrev.2024.05.040","url":null,"abstract":"<div><h3>Background</h3><div>Culprit-only percutaneous coronary intervention (PCI) is commonly performed for acute coronary syndrome<span> (ACS) with multivessel coronary artery disease<span> (MVD) in the elderly. Complete revascularization has been shown to benefit the general population, yet its safety and efficacy in older patients are uncertain.</span></span></div></div><div><h3>Methods</h3><div><span><span>Following PRISMA guidelines, we systematically searched PubMed, Embase, and Cochrane databases for </span>randomized controlled trials<span> (RCTs) comparing complete versus culprit-only PCI in patients ≥65 years old with ACS and MVD. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included myocardial infarction (MI), ischemia-driven revascularization (IDR), all-cause mortality, and cardiovascular mortality. Data were pooled using a random effects model with a restricted </span></span>maximum likelihood estimator to generate risk ratios (RRs).</div></div><div><h3>Results</h3><div>Five RCTs with 4105 patients aged ≥65 years were included. Compared with culprit-only PCI, complete revascularization reduced MI (RR 0.65; 95 % CI 0.49–0.85; <em>p</em> &lt; 0.01). MACE (RR 0.75; 95 % CI 0.54–1.05; <em>p</em> = 0.09) and IDR (RR 0.41; 95 % CI 0.16–1.04; <em>p</em> = 0.06) were not significantly different between both strategies among those aged ≥65. However, there was a significant reduction in MI (RR 0.69; 95 % CI 0.49–0.96; <em>p</em>-value = 0.03), MACE (RR 0.78; 95 % CI 0.65–0.94; <em>p</em> &lt; 0.01), and IDR (RR 0.60; 95 % CI 0.41–0.89; p &lt; 0.01) in those aged ≥75.</div></div><div><h3>Conclusions</h3><div>In elderly patients aged ≥65 years with ACS and MVD, a strategy of complete revascularization by PCI reduces MI compared to culprit-only PCI with no significant difference in MACE and IDR. However, complete revascularization reduced MI, MACE, and IDR in those aged ≥75 years suggesting a possible benefit in this age group.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141279886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}